Last reviewed · How we verify
PBR28 TSPO PET
At a glance
| Generic name | PBR28 TSPO PET |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TSPO Occupancy in the Human Lung (NA)
- Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure (PHASE2)
- Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients (PHASE2)
- Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR
- SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy (PHASE1, PHASE2)
- Imaging Inflammation in Alzheimer's Disease (PHASE2)
- Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)
- Measuring the Neuroimmune Response to Alcohol (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PBR28 TSPO PET CI brief — competitive landscape report
- PBR28 TSPO PET updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI